Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
Shares in
$AMGN rose to their highest level in the past year as a favorable ruling makes Enbrel sales through 2029 more secure. https://www.biopharmadive.com/news/amgen-resurgent-as-court-victory-for-top-drug-eases-doubts/560704/ …pic.twitter.com/mDBs2Py9oi
-
FDA could set record low for drug marketing warning letters — again https://bit.ly/2Qx7h9p pic.twitter.com/89F9CshJEY
-
The stock is down 90% today from the news. https://bit.ly/2Qk6qcC pic.twitter.com/iCUmaZSHXu
-
Top headline from yesterday: Regeneron and Bluebird team up on immuno-oncology. Analysis of what the could deal mean: https://bit.ly/2Odx1pW pic.twitter.com/hKe5XkTfn5
-
Almirall focused on Seysara, an antibiotic for acne vulgaris that it predicts will earn between $150 million and $200 million in peak annual sales. Almirall will pay up to $650 million to
$AGN in the deal. https://bit.ly/2LQsSLV pic.twitter.com/vtSi7aKuqT
-
BioPharma Dive Senior Editor Lisa LaMotta sat down with PwC to discuss the top
#health issues we are going to see in 2018. Stay tuned for more on 12/12! @BioWriterChik@KarenCYoung_#TopIssuespic.twitter.com/qQvp5c23xs
-
Roche's IMpower 150 study could shake up the I/O market https://www.biopharmadive.com/news/roche-lung-cancer-tecentriq-impower150/511326/ …pic.twitter.com/mlxqSRg4XB
-
Positive Ph. 3 results for
$ALNY's lead drug patisiran bring RNAi to the brink of becoming a medical reality http://bit.ly/2k9Ct39 pic.twitter.com/bTBfWOGjC8
-
Positive Ph. 3 results for
$ALNY's lead drug patisiran bring RNAi to the brink of becoming a medical reality http://bit.ly/2k9Ct39 pic.twitter.com/7QL2r1lSBR
-
Even after
$GILD opens wallet for$KITE, biopharma is sitting on a lot of cash: http://www.biopharmadive.com/news/industry-pulse-10-charts-on-ma-io-and-biosimilar-threats/504115/ …pic.twitter.com/WJ8VItUp3i
-
Who's at risk as biosimilars begin to emerge in US: http://www.biopharmadive.com/news/industry-pulse-10-charts-on-ma-io-and-biosimilar-threats/504115/ …pic.twitter.com/xyjcwmCR04
-
While
$GILD/$KITE deal has lifted biotech, major M&A few and far between in 2017: http://www.biopharmadive.com/news/industry-pulse-10-charts-on-ma-io-and-biosimilar-threats/504115/ …pic.twitter.com/RNBxsWPEAY
-
BioPharma Dive Editor Lisa LaMotta met with immuno-oncology investor
@bradloncar at#BIOCEO17 . Watch it here:https://youtu.be/97V8MX_PIi4e -
Love BioPharma Dive? Become a Dive Insider and earn perks like this snazzy shirt! Learn more: http://dive.pub/2hXMVop pic.twitter.com/Ns9yHc4ddL
-
TauRx Alzheimer's drug flunks late-stage study http://bit.ly/2avWxbt pic.twitter.com/Gz5FNpnBQZ
-
After scandal, China begins vaccine inspections nationwide http://bit.ly/2a848qP pic.twitter.com/I9kGP53eZL
-
Report: US drug prices often higher than in other developed countries http://bit.ly/29UvJMc pic.twitter.com/mkCsjYKAGN
-
Chinese team to test CRISPR in humans, jumping ahead of planned US study http://bit.ly/2aiWZGB pic.twitter.com/JbVnt39hPW
-
Post-censures, Theranos ramps up compliance efforts http://bit.ly/2afu8V6 pic.twitter.com/Z50K5gx1n7
-
Chinese team to test CRISPR in humans, jumping ahead of planned US study http://bit.ly/2aiWZGB pic.twitter.com/CfKJHeAZUm
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.